Canada is known for its universal, publicly funded health care system, often held up in American debates as an example. But Canada's system has a significant gap: outside hospitals, prescription drugs are not universally covered. Canadians rely on a patchwork of provincial programs, employer insurance and out-of-pocket payments. In 2024, Parliament passed a law intended to begin closing that gap through national pharmacare. Two years later, the program's expansion appears to have stalled [1][2].
What was promised
The Pharmacare Act, passed in 2024, laid out a first phase of national pharmacare focused on two categories of medicine: diabetes drugs, including insulin, and contraception. The plan was for the federal government to sign agreements with each province and territory, which run health care in Canada, to provide these medications free of charge to residents. Supporters described it as the foundation for broader, universal drug coverage in the future. Diabetes drugs and contraception were chosen partly because they are widely used and because cost can be a barrier to taking them consistently.
Who signed
Four jurisdictions signed agreements with the federal government: British Columbia, Manitoba, Prince Edward Island and Yukon [1][3][4]. Manitoba's agreement was announced in February 2025 [3]. British Columbia launched its new coverage on March 1, 2026, and Yukon's program began April 15, 2026, according to a summary of the agreements [1]. These agreements are scheduled to expire on March 31, 2029 [1].
The other provinces and territories, including Ontario, Quebec, Alberta, Saskatchewan,
Nova Scotia, New Brunswick and Newfoundland and Labrador, along with Nunavut and the Northwest Territories, do not have agreements [1]. Together, they are home to the large majority of Canadians.
The shift in Ottawa
Canada's federal government changed hands within the Liberal Party in 2025, with Mark Carney succeeding Justin Trudeau as prime minister. The new government has emphasized fiscal restraint. According to an analysis by the Canadian Centre for Policy Alternatives (CCPA) of the spring 2026 economic update presented by Finance Minister François-Philippe Champagne, the federal budget includes no new pharmacare funding beyond existing agreements, and bilateral health funding is set to fall from $4.3 billion in 2025-26 to $3.1 billion in 2027-28 (Canadian dollars) [1]. Federal officials have reportedly told some provinces that no new pharmacare deals will be signed and that existing deals will not be renewed after March 2029 [1]. Newfoundland and Labrador's government issued a public statement in February 2026 calling for "fair and equitable implementation of national pharmacare," arguing that its residents should not be left out [2]. Its health minister later said "the door was closed on our province," according to CBC reporting cited in the summary [1]. The federal government has said it remains committed to "honouring existing pharmacare agreements," and the Pharmacare Act has not been repealed [1]. But federal fiscal projections do not include funding to renew the agreements after 2029 [1].
Reactions
Advocates for universal pharmacare have reacted strongly. The CCPA has accused the government of "abandoning" national pharmacare, and the Council of Canadians and the Canadian Health Coalition called the intent to cut the program "unacceptable" [1]. They argue that without a national program, Canadians' access to essential medicines will continue to depend on where they live and where they work. The government and its supporters argue that Canada faces significant fiscal pressures, including higher defense spending and trade tensions with the United States, and that provinces can fund their own drug programs. Several provinces, including some that did not sign agreements, already have extensive public drug plans for seniors, low-income residents and people with high drug costs, and some provincial governments have long preferred to design their own programs rather than accept federal conditions.
How it compares to the United States
The debate in Canada mirrors questions in the United States, where drug costs are a constant political issue. The U.S. relies even more heavily on private insurance, but it has its own public drug programs, most notably Medicare Part D for older Americans, which since 2025 has capped annual out-of-pocket drug costs. Canada's experience shows that even in a country with universal hospital and doctor coverage, adding prescription drugs is expensive and politically difficult, especially when budgets tighten.
What patients pay today
Without national pharmacare, how much Canadians pay for prescriptions depends heavily on their circumstances. Most working-age Canadians with good jobs have drug coverage through employer insurance. Older adults and people on social assistance are usually covered by provincial plans. But many people, including those with low-wage or part-time jobs and the self-employed, fall into gaps where they pay large deductibles or the full cost. Advocates for pharmacare have long argued that these gaps lead some people to skip doses or not fill prescriptions, while opponents argue that targeted provincial programs are a more affordable way to help those in need.
PEI's funding cut
Prince Edward Island, one of the provinces that signed an agreement, has raised concerns about broader federal health funding. Its health minister said in April 2026 that Ottawa would cut more than $29 million in health care funding to the province over three years, according to the summary of provincial reactions [1]. The federal pharmacare contribution under existing agreements is scheduled to rise from $88.1 million in 2025-26 to $269.6 million in 2028-29 before the deals expire, but critics note that this is small compared with the cost of a national program [1].
Why it matters
Prescription drugs are one of the fastest-growing parts of health spending in most wealthy countries. Canada's pharmacare effort was meant to be the biggest expansion of its public health system in decades. Instead, it may end up as a limited program covering two kinds of medicine in a handful of provinces, with an expiration date. For Canadians in provinces without agreements, the cost of insulin or contraception will depend, as before, on their insurance and their province. For policymakers elsewhere, Canada offers a case study in how ambitious health reforms can stall when governments change priorities.
Sources
- 1. "Canada federal pharmacare withdrawal: bilateral deals expire, patients, provinces and advocates guide," RefDesk.ca, June 21, 2026 (summarizing CCPA analysis and CBC reporting). https://refdesk.ca/blog/canad a-federal-pharmacare-withdrawal-bilateral-deals-expire-june-21-2026-patients-provinces-advocates-guide
- 2. Government of Newfoundland and Labrador, "Newfoundland and Labrador Calls for Fair and Equitable Implementation of National Pharmacare," February 5, 2026. https://gov.nl.ca/releases/2026/exec/0205n01
- 3. Government of Canada, "Government of Canada signs pharmacare agreement with Manitoba to improve affordable access to medications," February 2025. https://www.canada.ca/en/health-canada/news/2025/02/ government-of-canada-signs-pharmacare-agreement-with-manitoba-to-improve-affordable-access-to-medic ations.html
- 4. "Government of Canada signs pharmacare agreement with Government of Yukon to improve universal access to free medications," Government of Yukon. https://yukon.ca/en/news/government-canada-signs-pha rmacare-agreement-government-yukon-improve-universal-access-free-medications Information in this article is current as of October 10, 2026. Bracketed numbers refer to the sources listed above.